SlideShare a Scribd company logo
1 of 42
DRUGS FOR CONSTIPATION
AND DIARRHEA
Dr. Resu Neha Reddy
MD Pharmcaology
Osmania Medical College
CONSTIPATION
 Common complaint in clinical practice.
 Definition of constipation includes the following:
 Infrequent bowel movements (typically three times or fewer per week)
 Difficulty during defecation
 The sensation of incomplete bowel evacuation.
 Rome III criteria are widely used to diagnose chronic constipation.
DIAGNOSTIC CRITERIA OF CONSTIPATION
 2 or more of criteria listed below:
 Straining efforts in course of defecation at least in 25% of defecations
 Solid stool at least in 25% of defecations
 Feeling of incomplete evacuation at least in 25% of defecations
 Feeling of anorectal obstruction at least in 25% of defecations
 Need in hand manipulation to facilitate the defecation at least in 25% of defecations
 Less than 3 defecations per week.
 Criteria fulfilled for the last 3 months with symptom onset.
PATHOPHYSIOLOGY
 Causes of constipation can be divided into primary and secondary.
 Most common - Primary or functional constipation is not due to any underlying cause.
 Secondary causes:
 Immobility
 Improper Diet
 Endocrine & Metabolic Disorders
 Neurological Disorders
 Psychological Conditions
 Structural Abnormalities
 Medications
MEDICATIONS ASSOCIATED WITH CONSTIPATION
 Aluminium and calcium containing antacids
 Anticholinergic agents
 Antidepressants
 Antipsychotics
 Iron
 Opioids
MANAGEMENT DRUGS FOR CONSTIPATION
1. LAXATIVE :- milder in action.
2. PURGATIVE :- stronger in action.
CLASSIFICATION
 BULK FORMING:-
a) Dietary fiber : Bran ,psyllium ,ispaghula ,methylcellulose
 STOOL SOFTENER:-
a) Docusates(DOSS), Liquid paraffin
 STIMULANT PURGATIVES:-
(a) Diphenylmethane- Phenolphthalein,Bisacodyl,sodium picosulfate
(b) Anthraquinones (emodins)- senna ,cascara sagrada
(c) 5-HT4 agonist- Prucalopride
(d) castor oil.
 OSMOTIC PURGATIVES:-
a) Magnesium salts: suflate,hydroxide
b) sodium salts: sulfate ,phosphate
c) sod.pot.tartrate
d) lactulose
BULK FORMING LAXATIVES
• DIETARY FIBRE BRAN :
• Residual product of flour industry which consist of 40% of dietary fiber.
• Consist of un-absorbable – cellulose , lignin, pectins, glycoprotiens & other polysaccharides.
• MECHANISM OF ACTION:-
• Absorbs water in the intestines, swells, increases water content of faeces- softens it and
facilitates colonic transit.
• Dietary fiber supports bacterial growth in colon which contribute to faecal mass.
DIETARY FIBRE BRAN
 First line approach for most patients of simple constipation.
 Reduces Recto sigmoid intraluminal pressure.
 Relieves symptoms of irritable bowel syndrome (IBS) including pain, constipation
as well as diarrhoea.
 DRAWBACKS
 Unpalatable
 Large quantity (20-40 g/day) needs
 Does not soften faeces already present in colon or rectum
 Should not be used in patients with gut ulcerations, adhesions.
PSYLLIUM & ISPAGHULA
 They contain natural colloidal mucilage
 MECHANISM OF ACTION:
 Forms a gelatinous mass by absorbing by water
 Largely fermented in colon increase bacterial mass & softens the faeces.
 USES:
 Useful in both constipation & diarrhea
 DRAWBACKS:
 If taken dry ,can cause esophageal impaction
 DOSE:
 3-12 g refined husk freshly mixed with water or milk and taken daily –acts in 1-3 days.
STOOL SOFTNER
 DOCUSATES (DIOCETYL SODIUM SULFOSUCCINATE:DOSS)
 It is a anionic detergent, softens the stool by decreasing the surface tension of fluids in
bowel.
 Emulsifies the colonic content and increases penetration of water into the faeces.
 DOSE: 100-400 mg/day
 USES: Indicated when straining at stools must be avoided.
 DRAWBACK:
 Can disrupt the mucosal barrier and enhance absorption of many non- absorbable drugs
 eg liquid- paraffin –should not be combined with it
 Cramps and abdominal pain can occur.
 Bitter; liquid preparation may cause nausea
LIQUID PARAFFIN
 It is a viscous liquid
 A mixture of petroleum hydrocarbon
 USES - Soften stools and is said to lubricate by coating them
 DOSE 15-30ml/day-oil as such or in emulsified form
 DRAWBACK
 Unpleasant to swallow
 Small amount passes in to intestinal mucosa →may produce foreign body granuloma
in intestinal submucosa.
 Carries away fat soluble vitamins with it into the stools; deficiency may occur on
chronic use
STIMULANT PURGATIVES
 DIPHENYLMETHANES: Phenolphthalein, Bisacodyl
 Activated in intestine by deactylation
 Site of acton is in colon: irritate the mucosa, produce mild inflammation → stimulate peristalsis.
 DOSE:
 Phenolphthalein: 60-130 mg
 Bisacodyl: 5-15 mg
 DRAWBACK:
 Allergic reaction- skin rashes, fixed drug eruption ,Stevens-Johnson syndrome have been reported.
 Phenolphthalein has been found to produce tumours in mice and genetic damage; the US-FDA has
ordered its withdrawal from market.
ANTHRAQUINONES
 Senna is obtained from leaves of certain Cassia sp.
 Cascara, sagrada is the powdered bark of the buck-thorn tree.
 These contain anthraquinone -glycosides ,also called Emodins.
 MECHANISM OF ACTION:-
 In the colon bacteria liberate the active anthrol form, which either acts locally or is absorbed into
circulation.
 The active principle acts on the myenteric plexus to increase peristalsis.
 DOSE: 12- 18 mg
 DRAWBACK:
 Skin rashes are seen occasionally
 Regular use for 4-12 months causes mucosal pigmentation (melanosis).
PRUCALOPRIDE
 It is a selective 5-HT4 receptor agonist marketed recently in UK, Europe and Canada for chronic
constipation, when other laxative fail.
 It activates 5-HT4 receptor on intrinsic enteric neurons to promoting propulsive contraction in
ileum and more prominently in colon
 Enhance release of excitatory transmitter Ach
 Colonic transit and stool frequency is improved - predominant irritable bowel syndrome.
 DOSE:- 2 mg OD.
 SIDE EFFECT:- Headache, dizziness, fatigue, abdominal pain & diarrhea.
CASTOR OIL
 Bland vegetable oil  the seeds of Ricinus communis
 MECHANISM OF ACTION:
It mainly contain triglyceride of ricinoleic acid which is a polar long chain fatty acid.
Castor oil hydrolyzed in the ileum by lipase to ricinoleic acid.
 Which acts primarily in the small intestine to stimulate secretion of fluid and electrolytes and
speed intestinal transit.
 DOSE: 30 ml oil
DRAWBACKS:
 unpalatable
 Frequent cramping, possibility of dehydration and after constipation (due to complete
evacuation of colon).
OSMOTIC PURGATIVE
 Solute that are not absorbed in the intestine retain water osmotically and distend the
bowel –increasing peristalsis indirectly.
 Magnesium salt also release cholecystokinin which augment motility and secretion.
 DOSE:
 Mag.hydroxide (as 8% w/w suspension-milk of magnesia) 30ml.
 Mag.sulfate : 5-15g.
 Sod.sulfate : 10-15g.
 Sod.phosphate: 6-12g
 Sod.pot.tartrate: 8-15g
 Salt taken in above mentioned doses, dissolved in 150-200 ml of water
 DRAWBACK:
 Unpleasant, vomiting, produce watery stool & after constipation
LACTULOSE
 It is a disaccharide of fructose and lactose which is neither
digested nor absorbed in the small intestine-retains water.
 It increase faecal bulk by hydrophilic action and also due to osmotic action.
 DOSE: 10 mg BD with plenty of water
 DRAWBACK:
 Flatulence and flatus is common, cramp also occur.
 Nausea due to its peculiar sweet taste.
ANTI-DIARRHOEAL AGENTS
DIARRHOEA
 It is defined by WHO as 3 or more loose or watery stool in a 24 hour period.
 Diarrhoeal diseases constitute a major cause of morbidity and mortality worldwide; especially in
developing counties.
 Globel burden of pediatric diarrhoea is estimated to be 1.5 billion episodes with 1.5-2.5 million
deaths under 5 year of age per year.
 In india around 1000 children die every day due to diarrhea.
 Main cause of death from acute diarrhoea is dehydration.
 Other important causes of death are dysentery and under-nutrition.
Types of Diarrhoea
 Acute Diarrhoea:
 Sudden onset and lasts less than two weeks
 90% are infectious in etiology
 Chronic Diarrhoea:
 Diarrhoea which lasts for more than 4 weeks
 Most of the causes are non-infectious
 Persistent Diarrhoea:
 Diarrhoea lasting between 2 to 4 weeks
PATHOPHYSIOLOGY
 The osmotic load of luminal contents plays an important role in determining final stool
water volume.
 When non-absorbable solutes are present and in disaccharidase deficiency (which
occurs during starvation), the stool water is increased.
 Inhibition of Na*K*ATPase and structural damage to mucosal cell (by Rota virus) causes
diarrhoea by reducing absorption
PATHOPHYSIOLOGY
 Intracellular cyclic nucleotides are important regulators
of absorptive and secretory processes.
 Stimuli enhancing cAMP or cGMP cause net loss of salt
and water, both by inhibiting NaCl absorption in villous
cells and by promoting anion secretion in the crypt cells
which are primarily secretory
MANAGEMENT
 Diarrhoea therapeutic measures may be grouped into:
A) Treatment of fluid depletion, shock and acidosis.
B) Maintenance of nutrition.
C) Drug therapy.
 Treatment of fluid depletion, shock & acidosis
 REHYDRATION:
 Done by (i) intravenous (ii) oral Intravenous rehydration:
 It is needed only when fluid loss is severe i.e., > 10% body weight,
 If patient is losing > 10 ml/kg/hr,
 unable to take enough oral fluids due to weakness, stupor or vomiting.
 The recommended composition of i.v. fluid is:
 NaCl 85mM = 5g in 1L of water
 KCI 13 mM = 1 g or 5% glucose
 NaHCO3 48mM = 4 g solution.
 Volume equivalent to 10% BW should be infused over 24 hours; the subsequent rate of
infusion is matched with the rate of fluid loss.
WHO ORS COMPOSITION
ADMINISTRATION OF ORT
 Patients are encouraged to drink ORS at ½-1 L hourly intervals.
 Initially 5-7.5% BW volume equivalent is given in 24 hours (5 ml/kg/hr in children).
 Subsequently it may be left to demand, but should at least cover the rate of loss in
stools.
ZINC IN PEDIATRIC DIARRHOEA
 WHO have recommended that all children with acute diarrhoea should be given zinc
supplementation along with ORS and continued for next 10-14 days.
 Zinc supplementation :
 10 mg/day for 0-6 month age
 20 mg/day for 6-60 month age
With ORS reduce the duration and severity of acute diarrhoea.
 Reduce recurrences of diarrhea for next 2-3 month.
MAINTENANCE OF NUTRITION
 Breast milk or ½ strength buffalo milk
 Boiled potato
 Cooked rice
 fruit juices
 chicken soup
 banana
 sago
should be given as soon as the patient can eat.
 Avoiding fats, high fibre foods and alcohol generally improves patient comfort.
DRUG THERAPY
 Drug used in diarrhea can be categorized in to
1. Specific antimicrobial drugs
2. Probiotics
3. Nonspecific anti-diarrhoeal drugs
DRUG THERAPY
 Antimicrobials are of no value : In diarrhoea due to non infective causes.
 Irritable bowel syndrome (IBS)
 Coeliac disease
 Pancreatic enzyme deficiency
 Thyrotoxicosis
 Rotavirus.
ANTIMICROBIAL ARE USEFUL ONLY IN SEVERE DISEASE
 TRAVELERS DIARRHOEA: mostly due to ETEC , campylobacter: cotrimoxazole, norfloxacin reduces the
duration.
 EPEC: is less common, but causes shigella like invasive illness. Cotrimoxazole or norfloxacin may be used in
acute cases and in infants
 YERSINIA ENTEROCOLITICA: common in colder places, cotrimoxazole is the most suitable drug in severe cases.
 SHIGELLA ENTERITIS: only when associated with blood and mucus in stools may be treated with ciprofloxacin
or norfloxin.
 SALMONELLA TYPHIMURIUM ENTERITIS is often invasive; severe cases may be treated with ciprofloxacin or
cotrimoxazole
PROBIOTIC IN DIARRHOEA
These are microbial cell preparation, either live culture or lyophilized powder
 Intended to be restore and maintain healthy gut flora.
 Diarrheal illnesses and antibiotic use are associated with alteration in the population, composition
and balance of gut microflora.
 Recolonization of gut by non-pathogenic, mostly lactic acid forming bacteria and yeast is believed
to help restore this balance.
 Organism most commonly used are
 Lactobacillus sp
 Bifidobacterium sp
 Streptococcus faecalis
 Enterococcus sp.
 yeast Saccharomyces boulardii.
NONSPECIFIC ANTIDIARRHOEAL AGENTS
 ABSORBANTS
 ISPAGHULA
 PSYLLIUM
 METHYLCELLULOSE
 ANTISECERTORY
 RECECADOTRIL
 BISMUTH SUBSALICYLATE
 ANTICHOLINERGICS
 OCTREOTIDE
 ANTIMOTILITY
 CODEINE
 DIPHENOXYLATE
 LOPERAMIDE
ABSORBANTS
 These are colloidal bulk forming substance which
absorb water & swell.
 They modify the consistency and frequency of stool
but do not reduce the water and electrolyte loss.
 ispaghula and other bulk forming colloids are useful
in both constipation and diarrhea.
ANTISECRETORY DRUGS
 RACECADOTRIL:
 This is a prodrug is rapidly converted to thiorphane ,an enkephalinase inhibitor.
 It prevent degradation of endogenous enkephalins(ENKs)
 MECHANISM OF ACTION: Decreases intestinal hypersecretion ,without affecting motility.
 DOSE: 100mg (children 1.5 mg/kg) TDS for 7 days
 DRAWBACK: Nausea, vomiting, drowsiness flatulence.
BISMUTH SUBSALICYLATE
 Bismuth is thought to have anti-secretory, anti-inflammatory, and antimicrobial effects.
 Mechanism of action:
 Stimulation of absorption of fluids and electrolytes by the intestinal wall (antisecretory action)
 Reducing inflammation/irritation of stomach through inhibition of prostaglandin
 Prevention and treatment of traveller's diarrhea, effective in other episodic diarrhea.
 DOSE: Taken as suspension 60 ml 6 hourly.
 DRAWBACK: Dark stools and black staining of the tongue
OCTREOTIDE
 Analog of somatostatin (SST), effective in inhibiting the severe secretory diarrhea
associated with hormone-secreting tumors of the pancreas and the GI tract.
 MECHANISM OF ACTION: inhibition of hormone secretion, including 5-HT and various
other GI peptides (e.g., gastrin, vasoactive intestinal polypeptide (VIP),secretin, etc.).
 USES:
 Diarrhoea associated with carcinoid and VIP secreting tumours
 Refractory diarrhea in AIDS.
 DOSE: 50 -100 µg given S.C 2-3 times a day
 DRAWBACK:
 Short-term therapy leads to nausea, bloating, or pain at sites of injection.
 Long-term therapy can lead to gallstone formation.
ANTIMOTILITY DRUG
 These are OPIODS drugs which increase small bowel tone and reduce propulsive
movement and diminish intestinal secretion while enhancing absorption.
Major action mediated through µ opioid receptor.
 Direct action on intestinal smooth muscle and secretory/ absorptive epithelium also
observed.
 δ receptor are promote absorption and inhibit secretion.
 µ receptor enhance absorption and decrease propulsive movement
DIPHENOXYLATE
 Synthetic opioids, used exclusively As anti-diarrheal agents.
 Available  small doses of atropine to discourage abuse.
 DOSE:
 25 µg atropine sulfate with 2.5 mg diphenoxylate
 Two tablets initially, then one tablet every 3-4 hours, not to
exceed eight tablets per day.
 DRAWBACK:
 CNS effects - higher doses (40-60 mg per day) and potential for
abuse and/or addiction.
 Respiratory depression, constipation
LOPERAMIDE
 Opiate analogue with major peripheral opioids and weak anticholinergic property.
 Anti-secretory activity against cholera toxin and some forms of Escherichia coli toxin,
 Gi-linked receptors  countering the increase in cellular cyclic AMP generated in
response to the toxins.
 DOSE:
 4mg followed by 2mg after each motion (max 10mg in a day)
 2mg BD for chronic Diarrhoea.
 DRAWBACK:
 Abdominal cramps and rashes are most common.
 Paralytic ileus, toxic megacolon, abdominal distension in young children.
 CNS effect are rare.
Drugs for constipation and diarrhea

More Related Content

What's hot

Digestants and Carminatives
Digestants and CarminativesDigestants and Carminatives
Digestants and CarminativesANUSHA SHAJI
 
Drugs used in treatment of constipation
Drugs used in treatment of constipationDrugs used in treatment of constipation
Drugs used in treatment of constipationSnehalChakorkar
 
Urinary Tract Infection
Urinary Tract InfectionUrinary Tract Infection
Urinary Tract InfectionRahul Kunkulol
 
Constipation and Diarrhoea
Constipation and DiarrhoeaConstipation and Diarrhoea
Constipation and DiarrhoeaDr. Imran Zaheer
 
Emetics and Anti-emetics (Pharmacology III)
Emetics and Anti-emetics (Pharmacology III)Emetics and Anti-emetics (Pharmacology III)
Emetics and Anti-emetics (Pharmacology III)MEHEDI HASAN
 
Anti ulcer drugs classification
Anti ulcer drugs classificationAnti ulcer drugs classification
Anti ulcer drugs classificationZulcaif Ahmad
 
Laxatives purgatives
Laxatives purgativesLaxatives purgatives
Laxatives purgativesRavish Yadav
 
Anti diarrheals
Anti diarrhealsAnti diarrheals
Anti diarrhealsRIPS-14
 
Leprosy; Antileprotic drugs
Leprosy; Antileprotic drugsLeprosy; Antileprotic drugs
Leprosy; Antileprotic drugsBikashAdhikari26
 
Appetite stimulants and suppressants-Anorexiants,Pharmacology
Appetite stimulants and suppressants-Anorexiants,PharmacologyAppetite stimulants and suppressants-Anorexiants,Pharmacology
Appetite stimulants and suppressants-Anorexiants,PharmacologyNishanth Arunodayam
 
Antiamoebic drugs
Antiamoebic drugsAntiamoebic drugs
Antiamoebic drugsFarazaJaved
 
Digestants, appetite stimulants and suppressants, Carminatives
Digestants, appetite stimulants and suppressants, CarminativesDigestants, appetite stimulants and suppressants, Carminatives
Digestants, appetite stimulants and suppressants, CarminativesKoppala RVS Chaitanya
 
Asthma and antiasthmatics
Asthma and antiasthmaticsAsthma and antiasthmatics
Asthma and antiasthmaticsDr.Vijay Talla
 
DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER SONALPANDE5
 
Urinary tract infection
Urinary tract infectionUrinary tract infection
Urinary tract infectionRaqshan Jabeen
 

What's hot (20)

Digestants and Carminatives
Digestants and CarminativesDigestants and Carminatives
Digestants and Carminatives
 
Sulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhritiSulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhriti
 
Drugs used in treatment of constipation
Drugs used in treatment of constipationDrugs used in treatment of constipation
Drugs used in treatment of constipation
 
Pharmacology of anti ulcer drugs
Pharmacology of anti ulcer drugsPharmacology of anti ulcer drugs
Pharmacology of anti ulcer drugs
 
Urinary Tract Infection
Urinary Tract InfectionUrinary Tract Infection
Urinary Tract Infection
 
Constipation and Diarrhoea
Constipation and DiarrhoeaConstipation and Diarrhoea
Constipation and Diarrhoea
 
Emetics and Anti-emetics (Pharmacology III)
Emetics and Anti-emetics (Pharmacology III)Emetics and Anti-emetics (Pharmacology III)
Emetics and Anti-emetics (Pharmacology III)
 
Anti ulcer drugs classification
Anti ulcer drugs classificationAnti ulcer drugs classification
Anti ulcer drugs classification
 
Laxatives purgatives
Laxatives purgativesLaxatives purgatives
Laxatives purgatives
 
Anti diarrheals
Anti diarrhealsAnti diarrheals
Anti diarrheals
 
Leprosy; Antileprotic drugs
Leprosy; Antileprotic drugsLeprosy; Antileprotic drugs
Leprosy; Antileprotic drugs
 
Appetite stimulants and suppressants-Anorexiants,Pharmacology
Appetite stimulants and suppressants-Anorexiants,PharmacologyAppetite stimulants and suppressants-Anorexiants,Pharmacology
Appetite stimulants and suppressants-Anorexiants,Pharmacology
 
Antiamoebic drugs
Antiamoebic drugsAntiamoebic drugs
Antiamoebic drugs
 
Antidiarrheals drug
Antidiarrheals drugAntidiarrheals drug
Antidiarrheals drug
 
Anti-tubercular agents
Anti-tubercular agentsAnti-tubercular agents
Anti-tubercular agents
 
Digestants, appetite stimulants and suppressants, Carminatives
Digestants, appetite stimulants and suppressants, CarminativesDigestants, appetite stimulants and suppressants, Carminatives
Digestants, appetite stimulants and suppressants, Carminatives
 
Asthma and antiasthmatics
Asthma and antiasthmaticsAsthma and antiasthmatics
Asthma and antiasthmatics
 
DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER
 
Antiulcer
AntiulcerAntiulcer
Antiulcer
 
Urinary tract infection
Urinary tract infectionUrinary tract infection
Urinary tract infection
 

Similar to Drugs for constipation and diarrhea

DRUGS FOR CONSTIPATION AND DIARRHEA
DRUGS FOR CONSTIPATION AND DIARRHEADRUGS FOR CONSTIPATION AND DIARRHEA
DRUGS FOR CONSTIPATION AND DIARRHEADinesh Kumar
 
Pharmacology of laxatives & antidiarrhoeal drugs
Pharmacology of laxatives & antidiarrhoeal drugsPharmacology of laxatives & antidiarrhoeal drugs
Pharmacology of laxatives & antidiarrhoeal drugsDr. Marya Ahsan
 
DRUGS USED FOR CONSTIPATION.pptx
DRUGS USED FOR CONSTIPATION.pptxDRUGS USED FOR CONSTIPATION.pptx
DRUGS USED FOR CONSTIPATION.pptxE Poovarasan
 
Drugs Used for treatment of Constipation & Diarrhoea
Drugs Used for treatment of Constipation & DiarrhoeaDrugs Used for treatment of Constipation & Diarrhoea
Drugs Used for treatment of Constipation & Diarrhoeaanujrims
 
Laxatives, diarrhoea & anti amoebic drugs
Laxatives, diarrhoea & anti amoebic drugsLaxatives, diarrhoea & anti amoebic drugs
Laxatives, diarrhoea & anti amoebic drugstamal111009
 
Antidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam K
Antidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam KAntidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam K
Antidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam KLVSimhachalam
 
Diarrhoea and constipation
Diarrhoea and constipationDiarrhoea and constipation
Diarrhoea and constipationBikashAdhikari26
 
Drugs used in gastrointestinal system
Drugs used in gastrointestinal systemDrugs used in gastrointestinal system
Drugs used in gastrointestinal systemsarosem
 
PICO-Executive's Copy.pptx
PICO-Executive's Copy.pptxPICO-Executive's Copy.pptx
PICO-Executive's Copy.pptxSabbir Ahmed
 
Gastrointestinal disorders
Gastrointestinal disorders Gastrointestinal disorders
Gastrointestinal disorders ABHIJIT BHOYAR
 
Constipation and dirrohea
Constipation and dirroheaConstipation and dirrohea
Constipation and dirroheaVishalGalave1
 

Similar to Drugs for constipation and diarrhea (20)

DRUGS FOR CONSTIPATION AND DIARRHEA
DRUGS FOR CONSTIPATION AND DIARRHEADRUGS FOR CONSTIPATION AND DIARRHEA
DRUGS FOR CONSTIPATION AND DIARRHEA
 
Constipation
Constipation Constipation
Constipation
 
Pharmacology of laxatives & antidiarrhoeal drugs
Pharmacology of laxatives & antidiarrhoeal drugsPharmacology of laxatives & antidiarrhoeal drugs
Pharmacology of laxatives & antidiarrhoeal drugs
 
drugs for constipation
drugs for constipation drugs for constipation
drugs for constipation
 
laxatives
laxativeslaxatives
laxatives
 
DRUGS USED FOR CONSTIPATION.pptx
DRUGS USED FOR CONSTIPATION.pptxDRUGS USED FOR CONSTIPATION.pptx
DRUGS USED FOR CONSTIPATION.pptx
 
Drugs Used for treatment of Constipation & Diarrhoea
Drugs Used for treatment of Constipation & DiarrhoeaDrugs Used for treatment of Constipation & Diarrhoea
Drugs Used for treatment of Constipation & Diarrhoea
 
Laxatives, diarrhoea & anti amoebic drugs
Laxatives, diarrhoea & anti amoebic drugsLaxatives, diarrhoea & anti amoebic drugs
Laxatives, diarrhoea & anti amoebic drugs
 
Constipation.pptx
Constipation.pptxConstipation.pptx
Constipation.pptx
 
Management of diarrhoea
Management of diarrhoeaManagement of diarrhoea
Management of diarrhoea
 
Antidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam K
Antidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam KAntidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam K
Antidiarrheal agents and Drugs for Constipation ppt - By Dr L V Simhachalam K
 
Constipation
ConstipationConstipation
Constipation
 
Diarrhoea and constipation
Diarrhoea and constipationDiarrhoea and constipation
Diarrhoea and constipation
 
Drugs used in gastrointestinal system
Drugs used in gastrointestinal systemDrugs used in gastrointestinal system
Drugs used in gastrointestinal system
 
PICO-Executive's Copy.pptx
PICO-Executive's Copy.pptxPICO-Executive's Copy.pptx
PICO-Executive's Copy.pptx
 
Treatment of diarrhea
Treatment of diarrheaTreatment of diarrhea
Treatment of diarrhea
 
Lactulose branding
Lactulose brandingLactulose branding
Lactulose branding
 
GI pharmacology
GI pharmacologyGI pharmacology
GI pharmacology
 
Gastrointestinal disorders
Gastrointestinal disorders Gastrointestinal disorders
Gastrointestinal disorders
 
Constipation and dirrohea
Constipation and dirroheaConstipation and dirrohea
Constipation and dirrohea
 

More from Dr Resu Neha Reddy

Drugs for Rheumatoid arthritis & gout
Drugs for Rheumatoid arthritis & goutDrugs for Rheumatoid arthritis & gout
Drugs for Rheumatoid arthritis & goutDr Resu Neha Reddy
 
Anti psychotics & anti manic drugs
Anti psychotics & anti manic drugsAnti psychotics & anti manic drugs
Anti psychotics & anti manic drugsDr Resu Neha Reddy
 
Pharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advancesPharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advancesDr Resu Neha Reddy
 
Angiotensin, kinins, leukotrienes, prostaglandins & cytokines
Angiotensin, kinins, leukotrienes, prostaglandins & cytokinesAngiotensin, kinins, leukotrienes, prostaglandins & cytokines
Angiotensin, kinins, leukotrienes, prostaglandins & cytokinesDr Resu Neha Reddy
 
Hypolipidemic drugs MBBS and PG Dr. Resu Neha Reddy
Hypolipidemic drugs MBBS and PG Dr. Resu Neha ReddyHypolipidemic drugs MBBS and PG Dr. Resu Neha Reddy
Hypolipidemic drugs MBBS and PG Dr. Resu Neha ReddyDr Resu Neha Reddy
 
Hypolipidemic drugs for Bsc nursing
Hypolipidemic drugs for Bsc nursing Hypolipidemic drugs for Bsc nursing
Hypolipidemic drugs for Bsc nursing Dr Resu Neha Reddy
 

More from Dr Resu Neha Reddy (20)

Alzheimer's disease pedogogy
Alzheimer's disease pedogogyAlzheimer's disease pedogogy
Alzheimer's disease pedogogy
 
Alzheimer's disease
Alzheimer's disease Alzheimer's disease
Alzheimer's disease
 
Quinolones & Fluoroquinolones
Quinolones & FluoroquinolonesQuinolones & Fluoroquinolones
Quinolones & Fluoroquinolones
 
Sedatives & hypnotics
Sedatives & hypnoticsSedatives & hypnotics
Sedatives & hypnotics
 
Drugs for Rheumatoid arthritis & gout
Drugs for Rheumatoid arthritis & goutDrugs for Rheumatoid arthritis & gout
Drugs for Rheumatoid arthritis & gout
 
Descriptive statistics
Descriptive statisticsDescriptive statistics
Descriptive statistics
 
Anti psychotics & anti manic drugs
Anti psychotics & anti manic drugsAnti psychotics & anti manic drugs
Anti psychotics & anti manic drugs
 
Anti hypertensive drugs
Anti hypertensive drugsAnti hypertensive drugs
Anti hypertensive drugs
 
Pharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advancesPharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advances
 
Antiviraldrugs
AntiviraldrugsAntiviraldrugs
Antiviraldrugs
 
Opioid analgesics nursing
Opioid analgesics nursingOpioid analgesics nursing
Opioid analgesics nursing
 
Nsaids dr.neha bds
Nsaids dr.neha bdsNsaids dr.neha bds
Nsaids dr.neha bds
 
Introduction to cns dr.neha
Introduction to cns dr.nehaIntroduction to cns dr.neha
Introduction to cns dr.neha
 
Antileprotic drugs
Antileprotic drugsAntileprotic drugs
Antileprotic drugs
 
Angiotensin, kinins, leukotrienes, prostaglandins & cytokines
Angiotensin, kinins, leukotrienes, prostaglandins & cytokinesAngiotensin, kinins, leukotrienes, prostaglandins & cytokines
Angiotensin, kinins, leukotrienes, prostaglandins & cytokines
 
Alcohol nursing
Alcohol   nursingAlcohol   nursing
Alcohol nursing
 
Beta blockers
Beta blockersBeta blockers
Beta blockers
 
Alpha blockers
Alpha blockersAlpha blockers
Alpha blockers
 
Hypolipidemic drugs MBBS and PG Dr. Resu Neha Reddy
Hypolipidemic drugs MBBS and PG Dr. Resu Neha ReddyHypolipidemic drugs MBBS and PG Dr. Resu Neha Reddy
Hypolipidemic drugs MBBS and PG Dr. Resu Neha Reddy
 
Hypolipidemic drugs for Bsc nursing
Hypolipidemic drugs for Bsc nursing Hypolipidemic drugs for Bsc nursing
Hypolipidemic drugs for Bsc nursing
 

Recently uploaded

GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)Areesha Ahmad
 
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)PraveenaKalaiselvan1
 
Botany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfBotany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfSumit Kumar yadav
 
Pests of cotton_Borer_Pests_Binomics_Dr.UPR.pdf
Pests of cotton_Borer_Pests_Binomics_Dr.UPR.pdfPests of cotton_Borer_Pests_Binomics_Dr.UPR.pdf
Pests of cotton_Borer_Pests_Binomics_Dr.UPR.pdfPirithiRaju
 
Nightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43b
Nightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43bNightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43b
Nightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43bSérgio Sacani
 
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsHubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsSérgio Sacani
 
Biological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdfBiological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdfmuntazimhurra
 
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...ssifa0344
 
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptxUnlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptxanandsmhk
 
Chromatin Structure | EUCHROMATIN | HETEROCHROMATIN
Chromatin Structure | EUCHROMATIN | HETEROCHROMATINChromatin Structure | EUCHROMATIN | HETEROCHROMATIN
Chromatin Structure | EUCHROMATIN | HETEROCHROMATINsankalpkumarsahoo174
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​kaibalyasahoo82800
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...Sérgio Sacani
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...Sérgio Sacani
 
Zoology 4th semester series (krishna).pdf
Zoology 4th semester series (krishna).pdfZoology 4th semester series (krishna).pdf
Zoology 4th semester series (krishna).pdfSumit Kumar yadav
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Sérgio Sacani
 
Pests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdfPests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdfPirithiRaju
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxAArockiyaNisha
 
DIFFERENCE IN BACK CROSS AND TEST CROSS
DIFFERENCE IN  BACK CROSS AND TEST CROSSDIFFERENCE IN  BACK CROSS AND TEST CROSS
DIFFERENCE IN BACK CROSS AND TEST CROSSLeenakshiTyagi
 
Botany krishna series 2nd semester Only Mcq type questions
Botany krishna series 2nd semester Only Mcq type questionsBotany krishna series 2nd semester Only Mcq type questions
Botany krishna series 2nd semester Only Mcq type questionsSumit Kumar yadav
 

Recently uploaded (20)

GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)
 
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)
 
Botany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfBotany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdf
 
Pests of cotton_Borer_Pests_Binomics_Dr.UPR.pdf
Pests of cotton_Borer_Pests_Binomics_Dr.UPR.pdfPests of cotton_Borer_Pests_Binomics_Dr.UPR.pdf
Pests of cotton_Borer_Pests_Binomics_Dr.UPR.pdf
 
Nightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43b
Nightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43bNightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43b
Nightside clouds and disequilibrium chemistry on the hot Jupiter WASP-43b
 
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroidsHubble Asteroid Hunter III. Physical properties of newly found asteroids
Hubble Asteroid Hunter III. Physical properties of newly found asteroids
 
Biological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdfBiological Classification BioHack (3).pdf
Biological Classification BioHack (3).pdf
 
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
 
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptxUnlocking  the Potential: Deep dive into ocean of Ceramic Magnets.pptx
Unlocking the Potential: Deep dive into ocean of Ceramic Magnets.pptx
 
Chromatin Structure | EUCHROMATIN | HETEROCHROMATIN
Chromatin Structure | EUCHROMATIN | HETEROCHROMATINChromatin Structure | EUCHROMATIN | HETEROCHROMATIN
Chromatin Structure | EUCHROMATIN | HETEROCHROMATIN
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
 
Zoology 4th semester series (krishna).pdf
Zoology 4th semester series (krishna).pdfZoology 4th semester series (krishna).pdf
Zoology 4th semester series (krishna).pdf
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
 
Pests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdfPests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdf
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
 
The Philosophy of Science
The Philosophy of ScienceThe Philosophy of Science
The Philosophy of Science
 
DIFFERENCE IN BACK CROSS AND TEST CROSS
DIFFERENCE IN  BACK CROSS AND TEST CROSSDIFFERENCE IN  BACK CROSS AND TEST CROSS
DIFFERENCE IN BACK CROSS AND TEST CROSS
 
Botany krishna series 2nd semester Only Mcq type questions
Botany krishna series 2nd semester Only Mcq type questionsBotany krishna series 2nd semester Only Mcq type questions
Botany krishna series 2nd semester Only Mcq type questions
 

Drugs for constipation and diarrhea

  • 1. DRUGS FOR CONSTIPATION AND DIARRHEA Dr. Resu Neha Reddy MD Pharmcaology Osmania Medical College
  • 2. CONSTIPATION  Common complaint in clinical practice.  Definition of constipation includes the following:  Infrequent bowel movements (typically three times or fewer per week)  Difficulty during defecation  The sensation of incomplete bowel evacuation.  Rome III criteria are widely used to diagnose chronic constipation.
  • 3. DIAGNOSTIC CRITERIA OF CONSTIPATION  2 or more of criteria listed below:  Straining efforts in course of defecation at least in 25% of defecations  Solid stool at least in 25% of defecations  Feeling of incomplete evacuation at least in 25% of defecations  Feeling of anorectal obstruction at least in 25% of defecations  Need in hand manipulation to facilitate the defecation at least in 25% of defecations  Less than 3 defecations per week.  Criteria fulfilled for the last 3 months with symptom onset.
  • 4. PATHOPHYSIOLOGY  Causes of constipation can be divided into primary and secondary.  Most common - Primary or functional constipation is not due to any underlying cause.  Secondary causes:  Immobility  Improper Diet  Endocrine & Metabolic Disorders  Neurological Disorders  Psychological Conditions  Structural Abnormalities  Medications
  • 5. MEDICATIONS ASSOCIATED WITH CONSTIPATION  Aluminium and calcium containing antacids  Anticholinergic agents  Antidepressants  Antipsychotics  Iron  Opioids
  • 6. MANAGEMENT DRUGS FOR CONSTIPATION 1. LAXATIVE :- milder in action. 2. PURGATIVE :- stronger in action.
  • 7. CLASSIFICATION  BULK FORMING:- a) Dietary fiber : Bran ,psyllium ,ispaghula ,methylcellulose  STOOL SOFTENER:- a) Docusates(DOSS), Liquid paraffin  STIMULANT PURGATIVES:- (a) Diphenylmethane- Phenolphthalein,Bisacodyl,sodium picosulfate (b) Anthraquinones (emodins)- senna ,cascara sagrada (c) 5-HT4 agonist- Prucalopride (d) castor oil.  OSMOTIC PURGATIVES:- a) Magnesium salts: suflate,hydroxide b) sodium salts: sulfate ,phosphate c) sod.pot.tartrate d) lactulose
  • 8. BULK FORMING LAXATIVES • DIETARY FIBRE BRAN : • Residual product of flour industry which consist of 40% of dietary fiber. • Consist of un-absorbable – cellulose , lignin, pectins, glycoprotiens & other polysaccharides. • MECHANISM OF ACTION:- • Absorbs water in the intestines, swells, increases water content of faeces- softens it and facilitates colonic transit. • Dietary fiber supports bacterial growth in colon which contribute to faecal mass.
  • 9. DIETARY FIBRE BRAN  First line approach for most patients of simple constipation.  Reduces Recto sigmoid intraluminal pressure.  Relieves symptoms of irritable bowel syndrome (IBS) including pain, constipation as well as diarrhoea.  DRAWBACKS  Unpalatable  Large quantity (20-40 g/day) needs  Does not soften faeces already present in colon or rectum  Should not be used in patients with gut ulcerations, adhesions.
  • 10. PSYLLIUM & ISPAGHULA  They contain natural colloidal mucilage  MECHANISM OF ACTION:  Forms a gelatinous mass by absorbing by water  Largely fermented in colon increase bacterial mass & softens the faeces.  USES:  Useful in both constipation & diarrhea  DRAWBACKS:  If taken dry ,can cause esophageal impaction  DOSE:  3-12 g refined husk freshly mixed with water or milk and taken daily –acts in 1-3 days.
  • 11. STOOL SOFTNER  DOCUSATES (DIOCETYL SODIUM SULFOSUCCINATE:DOSS)  It is a anionic detergent, softens the stool by decreasing the surface tension of fluids in bowel.  Emulsifies the colonic content and increases penetration of water into the faeces.  DOSE: 100-400 mg/day  USES: Indicated when straining at stools must be avoided.  DRAWBACK:  Can disrupt the mucosal barrier and enhance absorption of many non- absorbable drugs  eg liquid- paraffin –should not be combined with it  Cramps and abdominal pain can occur.  Bitter; liquid preparation may cause nausea
  • 12. LIQUID PARAFFIN  It is a viscous liquid  A mixture of petroleum hydrocarbon  USES - Soften stools and is said to lubricate by coating them  DOSE 15-30ml/day-oil as such or in emulsified form  DRAWBACK  Unpleasant to swallow  Small amount passes in to intestinal mucosa →may produce foreign body granuloma in intestinal submucosa.  Carries away fat soluble vitamins with it into the stools; deficiency may occur on chronic use
  • 13. STIMULANT PURGATIVES  DIPHENYLMETHANES: Phenolphthalein, Bisacodyl  Activated in intestine by deactylation  Site of acton is in colon: irritate the mucosa, produce mild inflammation → stimulate peristalsis.  DOSE:  Phenolphthalein: 60-130 mg  Bisacodyl: 5-15 mg  DRAWBACK:  Allergic reaction- skin rashes, fixed drug eruption ,Stevens-Johnson syndrome have been reported.  Phenolphthalein has been found to produce tumours in mice and genetic damage; the US-FDA has ordered its withdrawal from market.
  • 14. ANTHRAQUINONES  Senna is obtained from leaves of certain Cassia sp.  Cascara, sagrada is the powdered bark of the buck-thorn tree.  These contain anthraquinone -glycosides ,also called Emodins.  MECHANISM OF ACTION:-  In the colon bacteria liberate the active anthrol form, which either acts locally or is absorbed into circulation.  The active principle acts on the myenteric plexus to increase peristalsis.  DOSE: 12- 18 mg  DRAWBACK:  Skin rashes are seen occasionally  Regular use for 4-12 months causes mucosal pigmentation (melanosis).
  • 15. PRUCALOPRIDE  It is a selective 5-HT4 receptor agonist marketed recently in UK, Europe and Canada for chronic constipation, when other laxative fail.  It activates 5-HT4 receptor on intrinsic enteric neurons to promoting propulsive contraction in ileum and more prominently in colon  Enhance release of excitatory transmitter Ach  Colonic transit and stool frequency is improved - predominant irritable bowel syndrome.  DOSE:- 2 mg OD.  SIDE EFFECT:- Headache, dizziness, fatigue, abdominal pain & diarrhea.
  • 16. CASTOR OIL  Bland vegetable oil  the seeds of Ricinus communis  MECHANISM OF ACTION: It mainly contain triglyceride of ricinoleic acid which is a polar long chain fatty acid. Castor oil hydrolyzed in the ileum by lipase to ricinoleic acid.  Which acts primarily in the small intestine to stimulate secretion of fluid and electrolytes and speed intestinal transit.  DOSE: 30 ml oil DRAWBACKS:  unpalatable  Frequent cramping, possibility of dehydration and after constipation (due to complete evacuation of colon).
  • 17. OSMOTIC PURGATIVE  Solute that are not absorbed in the intestine retain water osmotically and distend the bowel –increasing peristalsis indirectly.  Magnesium salt also release cholecystokinin which augment motility and secretion.  DOSE:  Mag.hydroxide (as 8% w/w suspension-milk of magnesia) 30ml.  Mag.sulfate : 5-15g.  Sod.sulfate : 10-15g.  Sod.phosphate: 6-12g  Sod.pot.tartrate: 8-15g  Salt taken in above mentioned doses, dissolved in 150-200 ml of water  DRAWBACK:  Unpleasant, vomiting, produce watery stool & after constipation
  • 18. LACTULOSE  It is a disaccharide of fructose and lactose which is neither digested nor absorbed in the small intestine-retains water.  It increase faecal bulk by hydrophilic action and also due to osmotic action.  DOSE: 10 mg BD with plenty of water  DRAWBACK:  Flatulence and flatus is common, cramp also occur.  Nausea due to its peculiar sweet taste.
  • 20. DIARRHOEA  It is defined by WHO as 3 or more loose or watery stool in a 24 hour period.  Diarrhoeal diseases constitute a major cause of morbidity and mortality worldwide; especially in developing counties.  Globel burden of pediatric diarrhoea is estimated to be 1.5 billion episodes with 1.5-2.5 million deaths under 5 year of age per year.  In india around 1000 children die every day due to diarrhea.  Main cause of death from acute diarrhoea is dehydration.  Other important causes of death are dysentery and under-nutrition.
  • 21. Types of Diarrhoea  Acute Diarrhoea:  Sudden onset and lasts less than two weeks  90% are infectious in etiology  Chronic Diarrhoea:  Diarrhoea which lasts for more than 4 weeks  Most of the causes are non-infectious  Persistent Diarrhoea:  Diarrhoea lasting between 2 to 4 weeks
  • 22. PATHOPHYSIOLOGY  The osmotic load of luminal contents plays an important role in determining final stool water volume.  When non-absorbable solutes are present and in disaccharidase deficiency (which occurs during starvation), the stool water is increased.  Inhibition of Na*K*ATPase and structural damage to mucosal cell (by Rota virus) causes diarrhoea by reducing absorption
  • 23. PATHOPHYSIOLOGY  Intracellular cyclic nucleotides are important regulators of absorptive and secretory processes.  Stimuli enhancing cAMP or cGMP cause net loss of salt and water, both by inhibiting NaCl absorption in villous cells and by promoting anion secretion in the crypt cells which are primarily secretory
  • 24. MANAGEMENT  Diarrhoea therapeutic measures may be grouped into: A) Treatment of fluid depletion, shock and acidosis. B) Maintenance of nutrition. C) Drug therapy.
  • 25.  Treatment of fluid depletion, shock & acidosis  REHYDRATION:  Done by (i) intravenous (ii) oral Intravenous rehydration:  It is needed only when fluid loss is severe i.e., > 10% body weight,  If patient is losing > 10 ml/kg/hr,  unable to take enough oral fluids due to weakness, stupor or vomiting.  The recommended composition of i.v. fluid is:  NaCl 85mM = 5g in 1L of water  KCI 13 mM = 1 g or 5% glucose  NaHCO3 48mM = 4 g solution.  Volume equivalent to 10% BW should be infused over 24 hours; the subsequent rate of infusion is matched with the rate of fluid loss.
  • 27. ADMINISTRATION OF ORT  Patients are encouraged to drink ORS at ½-1 L hourly intervals.  Initially 5-7.5% BW volume equivalent is given in 24 hours (5 ml/kg/hr in children).  Subsequently it may be left to demand, but should at least cover the rate of loss in stools.
  • 28. ZINC IN PEDIATRIC DIARRHOEA  WHO have recommended that all children with acute diarrhoea should be given zinc supplementation along with ORS and continued for next 10-14 days.  Zinc supplementation :  10 mg/day for 0-6 month age  20 mg/day for 6-60 month age With ORS reduce the duration and severity of acute diarrhoea.  Reduce recurrences of diarrhea for next 2-3 month.
  • 29. MAINTENANCE OF NUTRITION  Breast milk or ½ strength buffalo milk  Boiled potato  Cooked rice  fruit juices  chicken soup  banana  sago should be given as soon as the patient can eat.  Avoiding fats, high fibre foods and alcohol generally improves patient comfort.
  • 30. DRUG THERAPY  Drug used in diarrhea can be categorized in to 1. Specific antimicrobial drugs 2. Probiotics 3. Nonspecific anti-diarrhoeal drugs
  • 31. DRUG THERAPY  Antimicrobials are of no value : In diarrhoea due to non infective causes.  Irritable bowel syndrome (IBS)  Coeliac disease  Pancreatic enzyme deficiency  Thyrotoxicosis  Rotavirus.
  • 32. ANTIMICROBIAL ARE USEFUL ONLY IN SEVERE DISEASE  TRAVELERS DIARRHOEA: mostly due to ETEC , campylobacter: cotrimoxazole, norfloxacin reduces the duration.  EPEC: is less common, but causes shigella like invasive illness. Cotrimoxazole or norfloxacin may be used in acute cases and in infants  YERSINIA ENTEROCOLITICA: common in colder places, cotrimoxazole is the most suitable drug in severe cases.  SHIGELLA ENTERITIS: only when associated with blood and mucus in stools may be treated with ciprofloxacin or norfloxin.  SALMONELLA TYPHIMURIUM ENTERITIS is often invasive; severe cases may be treated with ciprofloxacin or cotrimoxazole
  • 33. PROBIOTIC IN DIARRHOEA These are microbial cell preparation, either live culture or lyophilized powder  Intended to be restore and maintain healthy gut flora.  Diarrheal illnesses and antibiotic use are associated with alteration in the population, composition and balance of gut microflora.  Recolonization of gut by non-pathogenic, mostly lactic acid forming bacteria and yeast is believed to help restore this balance.  Organism most commonly used are  Lactobacillus sp  Bifidobacterium sp  Streptococcus faecalis  Enterococcus sp.  yeast Saccharomyces boulardii.
  • 34. NONSPECIFIC ANTIDIARRHOEAL AGENTS  ABSORBANTS  ISPAGHULA  PSYLLIUM  METHYLCELLULOSE  ANTISECERTORY  RECECADOTRIL  BISMUTH SUBSALICYLATE  ANTICHOLINERGICS  OCTREOTIDE  ANTIMOTILITY  CODEINE  DIPHENOXYLATE  LOPERAMIDE
  • 35. ABSORBANTS  These are colloidal bulk forming substance which absorb water & swell.  They modify the consistency and frequency of stool but do not reduce the water and electrolyte loss.  ispaghula and other bulk forming colloids are useful in both constipation and diarrhea.
  • 36. ANTISECRETORY DRUGS  RACECADOTRIL:  This is a prodrug is rapidly converted to thiorphane ,an enkephalinase inhibitor.  It prevent degradation of endogenous enkephalins(ENKs)  MECHANISM OF ACTION: Decreases intestinal hypersecretion ,without affecting motility.  DOSE: 100mg (children 1.5 mg/kg) TDS for 7 days  DRAWBACK: Nausea, vomiting, drowsiness flatulence.
  • 37. BISMUTH SUBSALICYLATE  Bismuth is thought to have anti-secretory, anti-inflammatory, and antimicrobial effects.  Mechanism of action:  Stimulation of absorption of fluids and electrolytes by the intestinal wall (antisecretory action)  Reducing inflammation/irritation of stomach through inhibition of prostaglandin  Prevention and treatment of traveller's diarrhea, effective in other episodic diarrhea.  DOSE: Taken as suspension 60 ml 6 hourly.  DRAWBACK: Dark stools and black staining of the tongue
  • 38. OCTREOTIDE  Analog of somatostatin (SST), effective in inhibiting the severe secretory diarrhea associated with hormone-secreting tumors of the pancreas and the GI tract.  MECHANISM OF ACTION: inhibition of hormone secretion, including 5-HT and various other GI peptides (e.g., gastrin, vasoactive intestinal polypeptide (VIP),secretin, etc.).  USES:  Diarrhoea associated with carcinoid and VIP secreting tumours  Refractory diarrhea in AIDS.  DOSE: 50 -100 µg given S.C 2-3 times a day  DRAWBACK:  Short-term therapy leads to nausea, bloating, or pain at sites of injection.  Long-term therapy can lead to gallstone formation.
  • 39. ANTIMOTILITY DRUG  These are OPIODS drugs which increase small bowel tone and reduce propulsive movement and diminish intestinal secretion while enhancing absorption. Major action mediated through µ opioid receptor.  Direct action on intestinal smooth muscle and secretory/ absorptive epithelium also observed.  δ receptor are promote absorption and inhibit secretion.  µ receptor enhance absorption and decrease propulsive movement
  • 40. DIPHENOXYLATE  Synthetic opioids, used exclusively As anti-diarrheal agents.  Available  small doses of atropine to discourage abuse.  DOSE:  25 µg atropine sulfate with 2.5 mg diphenoxylate  Two tablets initially, then one tablet every 3-4 hours, not to exceed eight tablets per day.  DRAWBACK:  CNS effects - higher doses (40-60 mg per day) and potential for abuse and/or addiction.  Respiratory depression, constipation
  • 41. LOPERAMIDE  Opiate analogue with major peripheral opioids and weak anticholinergic property.  Anti-secretory activity against cholera toxin and some forms of Escherichia coli toxin,  Gi-linked receptors  countering the increase in cellular cyclic AMP generated in response to the toxins.  DOSE:  4mg followed by 2mg after each motion (max 10mg in a day)  2mg BD for chronic Diarrhoea.  DRAWBACK:  Abdominal cramps and rashes are most common.  Paralytic ileus, toxic megacolon, abdominal distension in young children.  CNS effect are rare.